See the DrugPatentWatch profile for Zinbryta
What is Zinbryta, and what does it treat?
Zinbryta (daclizumab) is a medicine used for multiple sclerosis (MS). It was designed to reduce MS activity by changing immune signaling involved in the disease [1].
Why do people search for Zinbryta now?
A key reason is safety. Zinbryta has been associated with serious liver injury (including potentially fatal liver failure), as well as other immune-related complications. This led to strong regulatory action and restrictions in different markets over time [1].
Is Zinbryta still available?
Regulatory availability depends on the country. In many places, Zinbryta was withdrawn or restricted after the safety issues became clear, so access is not the same as for newer MS treatments [1].
What side effects are patients most concerned about?
The most prominent concern is liver damage, alongside other immune-mediated effects. Because of this, patients were generally monitored for liver-related problems during use [1].
What happened to Zinbryta compared with newer MS drugs?
Zinbryta is an older MS option compared with today’s mainstream MS therapies. As safety concerns drove withdrawal/restrictions, many patients and clinicians shifted to other approved disease-modifying therapies with different risk profiles [1].
Which sources explain Zinbryta’s safety history and regulatory status?
You can track the major safety and policy milestones in regulatory and product materials. A commonly referenced starting point is the U.S. prescribing information and the related safety communications [1].
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761053